Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) SVP Larry Todd Edwards sold 3,725 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $10.01, for a total transaction of $37,287.25. Following the completion of the transaction, the senior vice president now owns 136,635 shares in the company, valued at $1,367,716.35. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Arcutis Biotherapeutics Stock Performance
Shares of ARQT stock opened at $10.02 on Friday. The company has a market capitalization of $1.16 billion, a P/E ratio of -3.42 and a beta of 1.17. Arcutis Biotherapeutics, Inc. has a 52 week low of $1.76 and a 52 week high of $13.17. The company has a debt-to-equity ratio of 1.09, a quick ratio of 8.19 and a current ratio of 8.46. The company’s 50 day moving average price is $9.81 and its two-hundred day moving average price is $9.50.
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.06. The business had revenue of $30.86 million for the quarter, compared to analysts’ expectations of $31.00 million. Arcutis Biotherapeutics had a negative net margin of 150.51% and a negative return on equity of 145.41%. During the same period in the previous year, the firm posted ($1.16) EPS. On average, analysts expect that Arcutis Biotherapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.
Institutional Trading of Arcutis Biotherapeutics
Analysts Set New Price Targets
A number of equities research analysts recently commented on ARQT shares. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price objective on shares of Arcutis Biotherapeutics in a report on Thursday, August 15th. Jefferies Financial Group initiated coverage on Arcutis Biotherapeutics in a research report on Wednesday, August 28th. They set a “buy” rating and a $15.00 target price for the company. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $13.33.
Read Our Latest Stock Analysis on Arcutis Biotherapeutics
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
Further Reading
- Five stocks we like better than Arcutis Biotherapeutics
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What is MarketRank™? How to Use it
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Golden Cross Stocks: Pattern, Examples and Charts
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.